Our downstream process development teams can perform a variety of serotypes of AAV purification while supporting both column chromatography and ultracentrifugation. The optimization of the purification process involves various processes such as cell lysis, clarification, ultrafiltration concentration, affinity chromatography, ion exchange chromatography, sterilization and filtration, and formulation development, to obtain adeno-associated viruses with high purity, good activity, and low residue of impurities such as HCP/HCD, and to comprehensively consider production and process costs to confirm the optimal process parameters and purification route.

Porton Advanced has a dedicated viral vector production team with decades of hands-on and management experience.

We have established SF9 and HEK293 system processes, with a maximum capacity of 80 batch/year. The cGMP facility has an independent air conditioning system, a single-use and fully enclosed aseptic production process, and a unidirectional flow of personnel and logistics to minimize the risk of contamination and cross-contamination. The whole production operation can be monitored by CCTV, which can be preserved for further traceability, and all the production equipment has completed CSV (Computerized Systems Validation). The facility design and quality system meet the requirements of cGMP production management systems in China, the US, and the EU, allowing us to provide CDMO services for global clients.